Treatment of aggressive thyroid cancer with an oncolytic herpes virus Journal Article

Authors: Yu, Z.; Eisenberg, D. P.; Singh, B.; Shah, J. P.; Fong, Y.; Wong, R. J.
Article Title: Treatment of aggressive thyroid cancer with an oncolytic herpes virus
Abstract: Although many thyroid cancers carry a favorable prognosis, there is a subgroup of patients with more aggressive histologies. Current therapies offer no significant survival benefit to patients with anaplastic thyroid carcinomas, which are considered fatal. Oncolytic herpes simplex viruses (HSVs) have potent antitumor effects against a variety of human malignancies. We assessed the activity of a replication-competent, attenuated, oncolytic HSV (NV 1023) against 7 different thyroid cancers, including one papillary (NPA-187), one follicular (WRO82-1), one medullary (DRO81-1) and 4 anaplastic (DRO90-1, ARO, KAT-4C and KAT-18) cell lines. Only the follicular WRO82-1 line was resistant to NVI023 infection and cell lysis at a concentration of 5 viral pfu per cell (MOI 5). All other cell lines at NOI 5 demonstrated >95% infection in vitro at day 2 by X-gal staining and >88% cell death at day 4 by cytotoxicity assays. Even at NOI 0.1, 4 of these lines displayed complete cell death by day 7. Viral proliferation assays revealed that all of the non-follicular cell lines supported logarithmic viral replication. Flank tumors of NPA-187, DRO81-1, DRO90-1 and ARO in athymic nude mice were treated with NV1023 (2 × 10 7 pfu). All NPA-187 tumors completely regressed following a single dose. DRO81-1 tumors demonstrated partial response with a single dose and significant improvement with 3 serial doses. ARO and DRO90-1 tumors showed a significant response following either single injection (54 ± 22 and 292 ± 138 mm3, respectively) or 3 serial injections (33 ± 14 and 241 ± 68 mm3, respectively) compared to saline injections (472 ± 193 and 1,257 ± 204 mm3, respectively) at day 20. These data suggest that herpes oncolytic therapy may be effective for the treatment of aggressive thyroid carcinomas and merits further investigation. © 2004 Wiley-Liss, Inc.
Keywords: controlled study; human cell; dose response; nonhuman; antineoplastic agent; cell proliferation; mouse; animals; mice; cell death; carcinoma, papillary; animal experiment; animal model; cancer cell culture; cytotoxicity; tumor cells, cultured; statistical significance; mice, nude; staining; carcinoma; gene therapy; oncolytic virus; herpes virus; herpesvirus 1, human; thyroid cancer; thyroid neoplasms; virus replication; herpes; adenocarcinoma, follicular; live vaccine; carcinoma, medullary; virus vector; cell strain; oncolysis; virus vaccine; recombinant dna; humans; human; priority journal; article
Journal Title: International Journal of Cancer
Volume: 112
Issue: 3
ISSN: 0020-7136
Publisher: John Wiley & Sons  
Date Published: 2004-11-10
Start Page: 525
End Page: 532
Language: English
DOI: 10.1002/ijc.20421
PROVIDER: scopus
PUBMED: 15382081
Notes: Int. J. Cancer -- Cited By (since 1996):18 -- Export Date: 16 June 2014 -- CODEN: IJCNA -- Source: Scopus
Altmetric Score
MSK Authors
  1. Zhenkun Yu
    24 Yu
  2. Bhuvanesh Singh
    206 Singh
  3. Richard J Wong
    228 Wong
  4. Yuman Fong
    740 Fong
  5. Jatin P Shah
    538 Shah